For treatment-naïve adults with HIV-1. See Full Indication.

INTERACTIVE QUIZ FOR DOVATO

Chapter 2 of 6:  48-Week Primary Endpoint

Learning Progress

CHAPTER 1:

GEMINI 1 & 2 TRIAL DESIGNS

CHAPTER 2:

48-WEEK PRIMARY ENDPOINT

CHAPTER 3:

96-WEEK EFFICACY & RESISTANCE

CHAPTER 4:

DRUG-RELATED ADVERSE EVENTS

CHAPTER 5:

RESULTS IN HIGH VIRAL LOADS

CHAPTER 6:

BONE/RENAL BIOMARKERS

The estimated time to finish the whole learning experience is approximately 15 minutes.

CHAPTER 1:

GEMINI 1 & 2 TRIAL DESIGNS

CHAPTER 2:

48-WEEK PRIMARY ENDPOINT

CHAPTER 3:

96-WEEK EFFICACY & RESISTANCE

CHAPTER 4:

DRUG-RELATED ADVERSE EVENTS

CHAPTER 5:

RESULTS IN HIGH VIRAL LOADS

CHAPTER 6:

BONE/RENAL BIOMARKERS

The estimated time to finish the whole learning experience is approximately 15 minutes.

Delivers the Power of a DTG-Based 3-Drug Regimen at 48 Weeks With Rapid and Sustained Virologic Suppression  

Results Noninferior to DTG
+ TDF/FTC at Week 481,2*

GEMINI 1 & 2—POOLED VIROLOGIC RESPONSE BY VISIT (ITT-E; SNAPSHOT ANALYSIS)

GEMINI 1 & 2—POOLED VIROLOGIC RESPONSE BY VISIT (ITT-E; SNAPSHOT ANALYSIS)
Dovato_Charts_Mobile Rev 11ai

Patients With HIV-1 RNA <50 copies/mL, %

*ITT–E (intent-to-treat–exposed) population.

CDC=Centers for Disease Control and Prevention; DTG=dolutegravir; FTC=emtricitabine; HBV= hepatitis B virus; HCV=hepatitis C virus; TDF=tenofovir disoproxil fumarate.

TEST YOUR KNOWLEDGE!

Answer the following question relating to this chapter.

True or False: 91% of patients in the DOVATO arm achieved the primary endpoint of HIV-1 RNA <50 copies/mL at 48 weeks.

True

False

Answer to unlock

Next Chapter    >

References:

  1. Cahn P, Sierra Madero J, Arribas J, et al; and GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143-155.
  2. Data on file. ViiV Healthcare group of companies. Research Triangle Park, NC.

DLLWCNT200002